Dispersible tablet of erigeron breviscapus effective component extracts and preparation method thereof

Abstract

The invention relates to a medicinal preparation whose main medicinal constituent is the extract of active fleabane ingredient, and its preparing process, wherein the dispersible tablet comprises 10-80 wt% of the extract micro powder of active fleabane ingredient and balancing medicinal auxiliary materials, the preparation can be used for activating blood circulation, removing stasis, improving heart and brain blood circulation, and increasing anoxybiotic tolerant capacity, thus is mainly suitable for treating cardiovascular and cerebrovascular diseases and their after-effects, eyeground retina venous clogging, vasculitis skin diseases and rheumatosis.

Description

technical field [0001] The invention relates to a pharmaceutical preparation which takes active ingredient extract of breviscapine as the main medicinal ingredient and a preparation method thereof. technical background [0002] Erigeron breviseapus (Vant.) Hand.-Mazz is the dry whole herb of Erigeron breviseapus (Vant.) Hand.-Mazz. The folks in Yunnan call it Erigeron breviscapus, Erigeron breviscapus, and Asarum elegans, which have been included in the national standard. The original breviscapine extract products, Yimaikang and breviscapine capsules, are all based on the determination of the total flavonoids of breviscapine. The total flavonoids of breviscapine are isolated and extracted from breviscapine, mainly flavonoids, and the main components are scutellarin (scutellarin), scutellarin, apigenin, luteolin, baicalein, etc. The products extracted from Erigeron breviscapus are: the implementation standard is WS 3 -B-3823-98 Erigeron injection, the implementation standa...

AI Technical Summary

Problems solved by technology

The patent application for breviscapine and its extracts is also a hot spot in the field of medicine in recent years. There have been dozens of patent applications. The publication number is CN02153445.4 "Breviscapine Dispersible Tablets", which focuses on improving bioavailability and product stability. and appearance, but there are still the following defects: ① the bioavailability problem cannot be fundamentally solved without micronizing scutellarin; ② the technology used in the preparation method is relatively backward; ③ due to the yellow color and insufficient particle size of scutellarin, the The appearance is poor; ④The technical content of the product is low, and only a simple dosage form change has been made

Due to its poor solubility and glycoside compounds, the bioavailability of breviscapine flavonoids after oral administration to the human body is only about 10%. Therefore, improving the bioavailability of breviscapine extract preparations after oral administration is the key to its oral preparations. an important problem

In this regard, there are a lot of research at home and abroad, but the poor absorption of breviscapine flavonoids in the digestive tract has always hindered the clinical application of breviscapine extract, the main active ingredient flavonoids, and also restricted its ultimate Therefore, it has always been a difficult problem to overcome in pharmaceutical research.